Biogen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Biogen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. 

CEO
Christopher A. Viehbacher
CEOChristopher A. Viehbacher
Employees
7,605
Employees7,605
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
1978
Founded1978
Employees
7,605
Employees7,605

BIIB Key Statistics

Market cap
25.18B
Market cap25.18B
Price-Earnings ratio
15.65
Price-Earnings ratio15.65
Dividend yield
Dividend yield
Average volume
1.69M
Average volume1.69M
High today
$175.00
High today$175.00
Low today
$170.04
Low today$170.04
Open price
$173.17
Open price$173.17
Volume
1.08M
Volume1.08M
52 Week high
$190.20
52 Week high$190.20
52 Week low
$110.04
52 Week low$110.04

Stock Snapshot

With a market cap of 25.18B, Biogen(BIIB) trades at $171.59. The stock has a price-to-earnings ratio of 15.65.

As of 2026-01-25, Biogen(BIIB) stock has fluctuated between $170.04 and $175.00. The current price stands at $171.59, placing the stock +0.9% above today's low and -1.9% off the high.

The Biogen(BIIB)'s current trading volume is 1.08M, compared to an average daily volume of 1.69M.

During the past year, Biogen(BIIB) stock moved between $110.04 at its lowest and $190.20 at its peak.

During the past year, Biogen(BIIB) stock moved between $110.04 at its lowest and $190.20 at its peak.

BIIB News

Simply Wall St 15h
Assessing Biogen Valuation After New EU Approval For High Dose Spinraza

Biogen (BIIB) is back in focus after the European Commission approved a high dose regimen of SPINRAZA for 5q spinal muscular atrophy. The decision expands the t...

Assessing Biogen Valuation After New EU Approval For High Dose Spinraza
Simply Wall St 2d
High Dose SPINRAZA EU Approval Might Change The Case For Investing In Biogen

Biogen Inc. recently received European Commission marketing authorization for a new high dose regimen of SPINRAZA (nusinersen) to treat 5q spinal muscular atrop...

High Dose SPINRAZA EU Approval Might Change The Case For Investing In Biogen
Simply Wall St 4d
Biogen’s High Dose Spinraza Win Extends SMA Treatment Options In EU

European Commission grants marketing authorization for a high dose regimen of SPINRAZA for 5q spinal muscular atrophy. The decision expands available treatment...

Biogen’s High Dose Spinraza Win Extends SMA Treatment Options In EU

Analyst ratings

51%

of 37 ratings
Buy
43.2%
Hold
51.4%
Sell
5.4%

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.